METHODS FOR TREATING MUSCULAR DYSTROPHY
The present disclosure provides, among other things, improved compositions and methods for treating muscular dystrophy. For example, the disclosure provides methods for treating Duchenne muscular dystrophy patients having a mutation in the DMD gene that is amenable to exon 51 skipping by administering an effective amount of eteplirsen.
1 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly for more than 168 weeks, thereby maintaining ambulation relative to baseline in the patient, as measured by the 6 Minute Walk Test (6MWT).
2 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly for more than 168 weeks, thereby reducing the loss of ambulation relative to baseline in the patient, as measured by the 6 Minute Walk Test (6MWT).
3 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly for more than 168 weeks, thereby maintaining pulmonary function, or reducing the loss of pulmonary function, in the patient relative to baseline.
4 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly for more than 168 weeks, thereby restoring the mRNA reading frame to induce dystrophin protein production in the patient.
5 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly, thereby maintaining ambulation relative to baseline in the patient, as measured by the 6 Minute Walk Test (6MWT), thereby treating the patient, wherein the patient has lost the ability to rise independently from supine prior to treatment with eteplirsen.
6 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly, thereby maintaining ambulation relative to baseline in the patient, as measured by the 6 Minute Walk Test (6MWT), thereby treating the patient, wherein the patient loses the ability to rise independently from supine during treatment with eteplirsen.
7 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly, thereby reducing the loss of ambulation relative to baseline in the patient, as measured by the 6 Minute Walk Test (6MWT), wherein the patient has lost the ability to rise independently from supine prior to treatment with eteplirsen.
8 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly, thereby reducing the loss of ambulation relative to baseline in the patient, as measured by the 6 Minute Walk Test (6MWT), wherein the patient loses the ability to rise independently from supine during treatment with eteplirsen.
9 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly, thereby maintaining pulmonary function, or reducing the loss of pulmonary function, in the patient relative to baseline, wherein the patient has lost the ability to rise independently from supine prior to treatment with eteplirsen.
10 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly, thereby maintaining pulmonary function, or reducing the loss of pulmonary function, in the patient relative to baseline, wherein the patient loses the ability to rise independently from supine during treatment with eteplirsen.
11 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly, thereby restoring the mRNA reading frame to induce dystrophin protein production in the patient, wherein the patient has lost the ability to rise independently from supine prior to treatment with eteplirsen.
12 . A method for treating a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient eteplirsen at a dose of 30 mg/kg weekly, thereby restoring the mRNA reading frame to induce dystrophin protein production in the patient, wherein the patient loses the ability to rise independently from supine during treatment with eteplirsen.
13 .- 17 . (canceled)
18 . The method of claim 1 , wherein eteplirsen is intravenously administered to the patient weekly for at least 180 weeks.
19 . The method of claim 1 , wherein eteplirsen is intravenously administered to the patient weekly for at least 192 weeks.
20 . The method of claim 1 , wherein eteplirsen is intravenously administered to the patient weekly for more than 192 weeks
21 . The method of claim 1 , wherein eteplirsen is intravenously administered to the patient weekly for at least 216 weeks.
22 . The method of claim 3 , wherein pulmonary function is measured by Maximum Expiratory Pressure (MEP), Maximum Inspiratory Pressure (MIP), or Forced Vital Capacity (FVC).
23 . The method of claim 4 , wherein the dystrophin protein production is measured by reverse transcription polymerase chain reaction (RT-PCR), western blot analysis, or immunohistochemistry (IHC).
24 . The method of claim 20 , wherein the patient maintains a 6 Minute Walk Distance of at least 55 meters at 216 weeks of treatment.
25 . The method of claim 1 , wherein eteplirsen is administered as an intravenous infusion over 35 to 60 minutes.
26 . The method of claim 1 , further comprising confirming that the patient has a mutation in the DMD gene that is amenable to exon 51 skipping prior to administering eteplirsen.